Samuel Williams

Samuel Williams has a extensive work experience in the field of research and development, particularly in the biotechnology industry. Samuel started their career as a Research Assistant at Affymax in 1998. Later, they worked as a Graduate Student Researcher at Gladstone Institutes, where they focused on HIV latency and NF-kB signaling. Samuel continued their research as a Postdoctoral Fellow at Gladstone Institutes, investigating mechanisms supporting HIV latency. During this time, they made significant contributions to the field, resulting in publications in renowned journals.

In 2007, Samuel joined Genentech, Inc as a Postdoctoral Fellow, where they conducted research on the role of USP1 in osteosarcoma and its impact on tumor differentiation. Samuel identified USP1 as a deubiquitinase that stabilizes ID proteins and demonstrated that inhibition of USP1 or ID protein expression induces tumor differentiation.

From 2011 to 2016, Samuel worked at Stemcentrx, Inc as a Senior Scientist. Here, they led efforts in antibody drug conjugate (ADC) target discovery, validation, and early-stage development of preclinical oncology therapeutics. Samuel'steam also identified and characterized cancer stem cells in solid tumors.

In 2016, Samuel joined AbbVie Stemcentrx, LLC as a Principal Research Scientist after Stemcentrx's acquisition by AbbVie. In this role, they led antibody drug conjugate discovery and development for oncology therapeutic applications. Samuel also served as a project team lead for multiple preclinical development programs, resulting in multiple clinically evaluated therapeutics.

In 2018, Samuel became the Vice President of Research at Immutics, where they built and led a multidisciplinary team of over 40 scientists. Samuel'smain responsibilities included discovering and developing next-generation antibody-based immuno-oncology and anti-fibrotic therapeutics. Several of these therapeutics are currently in clinical evaluation for multiple disease settings.

Most recently, Samuel joined ArsenalBio in 2020 as the Vice President of Early Product Development. In this role, they lead the development of early-stage products in the biotechnology company.

Overall, Samuel Williams has a strong background in research and development, with a focus on oncology therapeutics, antibody-based immuno-oncology, and stem cell biology. Samuel has made significant contributions to the field and has a track record of successful project leadership and management.

Samuel Williams attended Stanford University where they obtained their Bachelor of Arts degree in Human Biology. Samuel later pursued their Ph.D. in Biomedical Sciences Program at the University of California, San Francisco. Prior to their university education, Samuel attended Henry M. Gunn High School. The specific start and end years are not provided for any of these educational experiences.